I understand your point of view but to keep claiming none of the c$&& is her fault doesn’t sit well with me based on her performance.
They may get tissue agnostic indication and it may even include Direct. Strategically she may be pretty good in that regard but it does not excuse her from acting like a normal company. May 10 and the last ASM was a culmination of a person unable to perform as CEO. You take questions and what you do not wish to give away you say “we cannot discuss this at this time”.
To have an ASM without financial or scheduling discussion is negligent and her performance is reflected in the share price. The deal with Advent is one topic that keeps hanging over this stock. It should be answered. It is easy to answer.
They filed their lawsuit, and in my opinion years late, and now we are here. 50 effing cents! It isn’t always someone else’s doing. No accredited analysts following this company shows her weakness to explain any of her actions or any realistic expectations. And for me, she has made some very bad choices.
I expect a tissue agnostic filing and this an integral product to treat all solid cancers. BUT, that does not mean I have no rights as a shareholder to have simple answers like this is how much we have spent to develop Eden to date and this is how much more we will burn to complete the task. Along with all present financial conditions on all aspects of the business. There are no real analysts following this company and no important Wall Street fund managers interested because of her. It is not Linda, Inc.
Market Data 
Markets 
AI
